Spexis AG
Develops therapeutics for rare diseases, oncology, and antimicrobial resistance.
SPEX | SW
Overview
Corporate Details
- ISIN(s):
- CH0106213793
- LEI:
- 391200S8HJE1I96FIG04
- Country:
- Switzerland
- Address:
- Hegenheimermattweg 125, 4123 Allschwil
- Website:
- https://www.polyphor.com/
- Sector:
- Manufacturing
Description
Spexis AG is a clinical-stage biopharmaceutical company focused on discovering and developing therapeutics for rare diseases and oncology. The company leverages its expertise in macrocycle technology to create novel drug candidates designed to address high unmet medical needs. Its pipeline is advanced through a strategy that includes in-house discovery, development, in-licensing, and the acquisition of promising molecules. The primary therapeutic areas of interest include rare diseases and cancer, with an additional focus on antimicrobial resistance.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2020-10-14 07:30 |
Polyphor receives CARB-X award of up to USD 18.44 million to support developmen…
|
English | 13.0 KB | ||
| 2020-09-29 07:00 |
Polyphor announces closing of Fosun Pharma licensing agreement for balixafortid…
|
English | 8.2 KB | ||
| 2020-09-11 18:50 |
Polyphor to present at the H.C. Wainwright Global Investment Conference
|
English | 7.4 KB | ||
| 2020-09-03 07:00 |
Polyphor announces financial results for the first half 2020
|
English | 21.6 KB | ||
| 2020-08-31 07:00 |
Polyphor and Fosun Pharma announce exclusive licensing agreement for balixafort…
|
English | 13.3 KB | ||
| 2020-08-03 07:00 |
Polyphor announces second positive Data Safety Monitoring Board recommendation …
|
English | 9.4 KB | ||
| 2020-07-28 07:00 |
Polyphor strengthens financial flexibility with CHF 19.3 million equity-linked …
|
English | 8.8 KB | ||
| 2020-06-04 17:35 |
Polyphor shareholders approve all proposals at the Annual General Meeting 2020
|
English | 9.3 KB | ||
| 2020-05-14 07:00 |
Polyphor announces acceptance of balixafortide abstract at the American Society…
|
English | 10.1 KB | ||
| 2020-05-05 07:00 |
Polyphor publishes invitation to the Annual General Meeting 2020
|
English | 11.3 KB | ||
| 2020-04-28 07:00 |
Polyphor announces financial results for the full-year 2019
|
English | 20.8 KB | ||
| 2020-03-30 07:00 |
Polyphor announces positive Data Safety Monitoring Board (DSMB) recommendation …
|
English | 9.4 KB | ||
| 2020-02-20 07:00 |
Polyphor announces progress of the Phase III immuno-oncology program with balix…
|
English | 16.5 KB | ||
| 2020-01-23 18:00 |
Polyphor appoints Gokhan Batur as Chief Executive Officer
|
English | 8.7 KB | ||
| 2019-11-20 07:00 |
Polyphor announces changes to its Board of Directors
|
English | 8.1 KB |
Automate Your Workflow. Get a real-time feed of all Spexis AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Spexis AG
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Spexis AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2022-06-21 | N/A | Executive member | Other | None | N/A |
Peer Companies
